Skip to main content
Delfa

← All trials/NCT07859176

Not yet recruitingPhase 4

Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery

Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery: a Randomized, Double-blind Trial

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

-

Estimated enrollment

100

Study population

Obesity / overweight

Eligibility highlights

-

Primary endpoint

•Body weight

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07859176
Org study IDTAPER Trial

Timeline

Milestones

Study first posted2026-10-05actual
Last update posted2026-10-05actual
Study start2026-10estimated (month precision)
Primary completion2028-04estimated (month precision)
Study completion2028-04estimated (month precision)

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Previous MBS of any type
•On semaglutide 2.4 mg (or maximum tolerated dose of at least 1.7 mg) for at least 6 months
•prescribed for recurrent weight gain or suboptimal response
•Weight stable within 3% over the last 12 weeks
•Patient and physician have decided to discontinue

Exclusion criteria

•Type 2 diabetes requiring continued GLP-1 therapy
•Planned revisional surgery within the study period
•Pregnancy or conception planned within the study; obesity pharmacotherapy is stopped at least 2 months before any planned conception per current labeling and the 2026 Standards, and such patients follow that pathway, not this protocol
•Concurrent use of any other obesity medication

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
5
Other (unclassified)
3
Glycemic / diabetes
1
Cardiometabolic biomarkers
1

Weight & body composition

5 endpoints
Primary/protocol endpoint

Percentage change in body weight

Time frame:Baseline till 18 months

percent change from baseline, improvement

Secondary/protocol endpoint

Weight change

Time frame:6, 18 months

descriptive

Secondary/protocol endpoint

Proportion weight

Time frame:baseline till 18 months

threshold achievement, improvement

Secondary/protocol endpoint

Recurrent weight gain

Time frame:Baseline till 18 months

descriptive

Secondary/protocol endpoint

waist circumference

Time frame:0, 6, 12 months

descriptive

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

change in HbA1c

Time frame:0, 6, 12 months

change from baseline, improvement

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

total cholesterol, LDL, HDL, and triglycerides

Time frame:0, 6, 12 months

descriptive

Other (unclassified)

3 endpoints
Secondary/protocol endpoint/low confidence

Time to pharmacotherapy restart

Time frame:Baseline till 18 months

time to event, event

Secondary/protocol endpoint/low confidence

Hand-grip strength

Time frame:0, 6, 12 months

descriptive

Secondary/protocol endpoint/low confidence

De novo restrictive eating behavior

Time frame:0, 6, 12, 18 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateNovember 5, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.